New biopsy technique aims to better spot dangerous prostate cancers
NCT ID NCT06482645
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a newer biopsy method (perilesional biopsy) can find aggressive prostate cancers as well as the standard combination of targeted and systematic biopsies. About 640 men with a single suspicious MRI lesion will be randomly assigned to one of two biopsy approaches. The goal is to see which method detects clinically significant cancers more accurately while reducing detection of low-risk cancers that don't need treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
biopsy procedure
What this could lead to
If successful, this could help doctors choose the best biopsy method to find aggressive prostate cancers while avoiding unnecessary detection of harmless ones.
What could go wrong
This is a diagnostic study, not a treatment trial. Results may not change practice if the new method misses some cancers or causes more complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••